For the quarter ending 2025-09-30, CYTK had $152,028K increase in cash & cash equivalents over the period. -$116,859K in free cash flow.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -306,178 | -295,746 |
| Non-cash interest expense on liabilities related to revenue participation right purchase agreements | 14,995 | 27,311 |
| Stock-based compensation expense | 30,696 | 51,084 |
| Non-cash lease expense | 1,472 | 2,566 |
| Depreciation of property and equipment | 2,679 | 4,585 |
| Change in fair value of derivative liabilities | 700 | 2,600 |
| Change in fair value of liabilities related to rpi transactions | -2,800 | -10,700 |
| Realized gain on investment, net | 1 | 16 |
| Interest receivable and amortization on investments | -2,696 | -10,206 |
| Non-cash interest expense related to debt | 5,648 | 8,783 |
| Debt conversion expense | 121,249 | - |
| Accounts receivable | -6,602 | -8,240 |
| Prepaid and other assets | -6,277 | 5,013 |
| Accounts payable | 6,598 | -3,626 |
| Deferred revenue | 268 | -51,026 |
| Accrued and other liabilities | 7,617 | -382 |
| Operating lease liabilities | -2,150 | -4,466 |
| Other non-current liabilities | -2,681 | -41 |
| Net cash used in operating activities | -107,505 | -259,853 |
| Purchases of investments | 335,452 | 382,071 |
| Investment in non-marketable equity security | 0 | 5,000 |
| Maturities of investments | 273,826 | 549,725 |
| Sales of investments | 1 | 5,992 |
| Purchases of property and equipment | 9,354 | 9,809 |
| Net cash provided by (used in) investing activities | -70,979 | 158,837 |
| Repayment of finance lease liabilities | 0 | 204 |
| Repayment of term loans | 2,709 | 5,378 |
| Repayment of convertible debt | 402,500 | - |
| Proceeds from issuance of convertible debt, net | 729,460 | - |
| Proceeds from rpi transactions | 0 | 75,000 |
| Proceeds from issuance of common stock related to at-the-market offering, net of issuance costs-At The Market Offering | 0 | 0 |
| Proceeds from issuance of common stock related to at-the-market offering, net of issuance costs-Public Offering | 0 | 0 |
| Proceeds from issuance of common stock related to private placement, net of issuance costs | 0 | 0 |
| Proceeds from issuance of common stock under equity incentive and stock purchase plans | 6,935 | 14,396 |
| Taxes paid related to net share settlement of equity awards | 720 | 527 |
| Net cash provided by financing activities | 330,466 | 83,287 |
| Effect of exchange rate changes on cash | 46 | -952 |
| Net (decrease) increase in cash, cash equivalents, and restricted cash | 152,028 | -18,681 |
| Cash and cash equivalents at beginning of period | 95,232 | - |
| Cash and cash equivalents at end of period | 228,579 | - |
CYTOKINETICS INC (CYTK)
CYTOKINETICS INC (CYTK)